NCT02780713View on ClinicalTrials.gov

A Study to Assess the Pharmacokinetics and Safety of Different Forms and Formulations of AZD9496 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

June 2, 2016

Primary Completion Date

September 20, 2016

Study Completion Date

September 20, 2016

Conditions
Breast Cancer
Interventions
DRUG

AZD9496 (Reference)

AZD9496 (Reference)

DRUG

AZD9496 Variant A

AZD9496 Variant A.

DRUG

AZD9496 Variant B

AZD9496 Variant B

DRUG

AZD9496 Variant C

AZD9496 Variant C

DRUG

AZD9496 Variant D

AZD9496 Variant D

Trial Locations (1)

21225

Research Site, Baltimore

Sponsors

Lead Sponsor

AstraZeneca

Collaborators (1)

Parexel
All Listed Sponsors
collaborator

Parexel

INDUSTRY

lead

AstraZeneca

INDUSTRY